IMFINZI plus tarlatamab interim DeLLphi-305 data show OS and PFS gains
Planned interim analysis of DeLLphi-305 Phase III showed IMFINZI (durvalumab) plus tarlatamab delivered statistically significant improvement in overall survival versus IMFINZI alone in 1st-line extensive-stage small cell lung cancer, with progression-free survival also improved.